SBI 302
Alternative Names: SBI-302Latest Information Update: 30 May 2025
At a glance
- Originator SHIFTBIO
- Class RNA
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 02 Apr 2025 Early research in Unspecified in South Korea (unspecified route), prior to April 2025 (Shiftbio pipeline, April 2025)